Intensive glucose control after allogeneic hematopoietic stem cell transplantation

A retrospective matched-cohort study

S. Fuji, S. W. Kim, S. Mori, S. Kamiya, K. Yoshimura, H. Yokoyama, S. Kurosawa, B. Saito, T. Takahashi, S. Kuwahara, Y. Heike, Ryuji Tanosaki, Y. Takaue, T. Fukuda

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalBone Marrow Transplantation
Volume44
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Cohort Studies
Glucose
Control Groups
Incidence
Hematologic Neoplasms
Bacteremia
Least-Squares Analysis
Proportional Hazards Models
C-Reactive Protein
Intensive Care Units
Stem Cells
Tissue Donors
Prospective Studies
Kidney

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Intensive glucose control after allogeneic hematopoietic stem cell transplantation : A retrospective matched-cohort study. / Fuji, S.; Kim, S. W.; Mori, S.; Kamiya, S.; Yoshimura, K.; Yokoyama, H.; Kurosawa, S.; Saito, B.; Takahashi, T.; Kuwahara, S.; Heike, Y.; Tanosaki, Ryuji; Takaue, Y.; Fukuda, T.

In: Bone Marrow Transplantation, Vol. 44, No. 2, 2009, p. 105-111.

Research output: Contribution to journalArticle

Fuji, S, Kim, SW, Mori, S, Kamiya, S, Yoshimura, K, Yokoyama, H, Kurosawa, S, Saito, B, Takahashi, T, Kuwahara, S, Heike, Y, Tanosaki, R, Takaue, Y & Fukuda, T 2009, 'Intensive glucose control after allogeneic hematopoietic stem cell transplantation: A retrospective matched-cohort study', Bone Marrow Transplantation, vol. 44, no. 2, pp. 105-111. https://doi.org/10.1038/bmt.2008.431
Fuji, S. ; Kim, S. W. ; Mori, S. ; Kamiya, S. ; Yoshimura, K. ; Yokoyama, H. ; Kurosawa, S. ; Saito, B. ; Takahashi, T. ; Kuwahara, S. ; Heike, Y. ; Tanosaki, Ryuji ; Takaue, Y. ; Fukuda, T. / Intensive glucose control after allogeneic hematopoietic stem cell transplantation : A retrospective matched-cohort study. In: Bone Marrow Transplantation. 2009 ; Vol. 44, No. 2. pp. 105-111.
@article{652f2f6edc2a42658c436eb1bb2ac148,
title = "Intensive glucose control after allogeneic hematopoietic stem cell transplantation: A retrospective matched-cohort study",
abstract = "Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46{\%}, P = 0.004, 9 vs 39{\%}, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37{\%}, P = 0.36) and the elevation of C-reactive protein (18 vs 38{\%}, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.",
author = "S. Fuji and Kim, {S. W.} and S. Mori and S. Kamiya and K. Yoshimura and H. Yokoyama and S. Kurosawa and B. Saito and T. Takahashi and S. Kuwahara and Y. Heike and Ryuji Tanosaki and Y. Takaue and T. Fukuda",
year = "2009",
doi = "10.1038/bmt.2008.431",
language = "English",
volume = "44",
pages = "105--111",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Intensive glucose control after allogeneic hematopoietic stem cell transplantation

T2 - A retrospective matched-cohort study

AU - Fuji, S.

AU - Kim, S. W.

AU - Mori, S.

AU - Kamiya, S.

AU - Yoshimura, K.

AU - Yokoyama, H.

AU - Kurosawa, S.

AU - Saito, B.

AU - Takahashi, T.

AU - Kuwahara, S.

AU - Heike, Y.

AU - Tanosaki, Ryuji

AU - Takaue, Y.

AU - Fukuda, T.

PY - 2009

Y1 - 2009

N2 - Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.

AB - Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.

UR - http://www.scopus.com/inward/record.url?scp=68149129628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149129628&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.431

DO - 10.1038/bmt.2008.431

M3 - Article

VL - 44

SP - 105

EP - 111

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -